DiscoverWTR Healthcare HappeningsPharmAla Biotech’s CEO Nick Kadysh On Psychedelics, the FDA, and PharmAla’s Strategic Approach Post-Lykos CRL
PharmAla Biotech’s CEO Nick Kadysh On Psychedelics, the FDA, and PharmAla’s Strategic Approach Post-Lykos CRL

PharmAla Biotech’s CEO Nick Kadysh On Psychedelics, the FDA, and PharmAla’s Strategic Approach Post-Lykos CRL

Update: 2025-10-22
Share

Description

In this episode of WTR Healthcare Happenings, WTR's Tim Gerdeman, and Robert Sassoon welcomes back Nick Kadysh, Founding CEO and President of PharmAla Biotech (OTCQB: MDXXF). The discussion explores the evolving global regulatory environment for psychedelics—particularly MDMA—the ripple effects of the Lykos Therapeutics FDA Complete Response Letter (CRL) disclosures, and PharmAla’s strategic approach to research, manufacturing, and commercialization of clinical-grade MDMA and next-generation analogues.

Comments 
In Channel
Zomedica's (OTCQB: ZOMDF) CEO Highlights Its Innovative Product Offerings and Significant Growth Opportunities in the Animal Healthcare Market

Zomedica's (OTCQB: ZOMDF) CEO Highlights Its Innovative Product Offerings and Significant Growth Opportunities in the Animal Healthcare Market

2025-05-2817:48

Enlivex Therapeutics CEO Oren Hershkovitz, PhD Discusses Allocetra Cell Therapy and Recent Knee Osteoarthritis Data

Enlivex Therapeutics CEO Oren Hershkovitz, PhD Discusses Allocetra Cell Therapy and Recent Knee Osteoarthritis Data

2025-05-2127:34

Most-Favored-Nation Drug Pricing Lacks Executive Plan

Most-Favored-Nation Drug Pricing Lacks Executive Plan

2025-05-1409:09

PharmAla Biotech’s CEO Nick Kadysh On Psychedelics, the FDA, and PharmAla’s Strategic Approach Post-Lykos CRL

PharmAla Biotech’s CEO Nick Kadysh On Psychedelics, the FDA, and PharmAla’s Strategic Approach Post-Lykos CRL

2025-10-2220:37

CEO Dr. Amit Kumar Discusses Anixa Biosciences' Innovative Approach to Help T-Cells Address Solid Tumors

CEO Dr. Amit Kumar Discusses Anixa Biosciences' Innovative Approach to Help T-Cells Address Solid Tumors

2025-10-1524:18

Veru's CEO Mitch Steiner on Enobosarm's value-added to the booming GLP-1 Weight Loss Drug Market

Veru's CEO Mitch Steiner on Enobosarm's value-added to the booming GLP-1 Weight Loss Drug Market

2025-10-0821:35

Revolutionizing Stroke Prevention: InspireMD’s CGuard® Prime and the Future of Carotid Stenting

Revolutionizing Stroke Prevention: InspireMD’s CGuard® Prime and the Future of Carotid Stenting

2025-09-2419:15

Transforming Global Healthcare Access: Doc.com’s Mission for Free Basic Telemedicine

Transforming Global Healthcare Access: Doc.com’s Mission for Free Basic Telemedicine

2025-09-1824:19

Psychedelics Sector Deals 2025: AbbVie/Gilgamesh Impact and Market Outlook

Psychedelics Sector Deals 2025: AbbVie/Gilgamesh Impact and Market Outlook

2025-09-0306:55

Ludwig's Dr. Marvin Hausman on Why Its Cheek-Swabbing mRNA Technology Platform Promises to be a Revolutionary Diagnostic Tool

Ludwig's Dr. Marvin Hausman on Why Its Cheek-Swabbing mRNA Technology Platform Promises to be a Revolutionary Diagnostic Tool

2025-08-1934:22

CEO Brent Lucas on Why Envoy Medical's Device Technology is Currently the Only Change Agent in Hearing Health

CEO Brent Lucas on Why Envoy Medical's Device Technology is Currently the Only Change Agent in Hearing Health

2025-08-1331:33

Ainos' Director of Corporate Development Jack Lu on Why SmellTech Platform AI Nose is a Foundational Product in AI

Ainos' Director of Corporate Development Jack Lu on Why SmellTech Platform AI Nose is a Foundational Product in AI

2025-07-2223:44

Lisata Therapeutics' CEO Dr. David Mazzo and CMO Dr. Kristen Buck On the Promise Of Certepetide for Pancreatic Cancer

Lisata Therapeutics' CEO Dr. David Mazzo and CMO Dr. Kristen Buck On the Promise Of Certepetide for Pancreatic Cancer

2025-07-1823:27

Cybin CEO Doug Drysdale On What Distinguishes CYB003 from Other Aspiring Novel Depression Treatments

Cybin CEO Doug Drysdale On What Distinguishes CYB003 from Other Aspiring Novel Depression Treatments

2025-07-1421:04

A Conversation with PharmAla Biotech CEO Nick Kadysh on What the Trump FDA and AI mean for the Biotech Landscape

A Conversation with PharmAla Biotech CEO Nick Kadysh on What the Trump FDA and AI mean for the Biotech Landscape

2025-06-2524:20

Trevi Therapeutics CEO Jennifer Good Discusses Oral Haduvio Benefit in Chronic Cough

Trevi Therapeutics CEO Jennifer Good Discusses Oral Haduvio Benefit in Chronic Cough

2025-06-1829:31

How the Biomarker Era Will Transform the CNS Treatment Landscape with Psilera CEO Dr. Chris Witowski

How the Biomarker Era Will Transform the CNS Treatment Landscape with Psilera CEO Dr. Chris Witowski

2025-06-1214:57

Apimeds Pharmaceuticals CEO Erik Emerson Discusses Purified Bee Venom for Knee Osteoarthritis and Other Inflammatory Conditions

Apimeds Pharmaceuticals CEO Erik Emerson Discusses Purified Bee Venom for Knee Osteoarthritis and Other Inflammatory Conditions

2025-06-1129:42

Current State of Biotech, Market Pressure Points, Obesity and PD-1/VEGF

Current State of Biotech, Market Pressure Points, Obesity and PD-1/VEGF

2025-05-0818:59

WTR Biotech Flashcast: Neuroscience, Alzheimer’s and Biogen IOC

WTR Biotech Flashcast: Neuroscience, Alzheimer’s and Biogen IOC

2025-04-2416:01

loading
Google Play
Download from Google Play
Castbox
Download from App Store
usUnited States
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

PharmAla Biotech’s CEO Nick Kadysh On Psychedelics, the FDA, and PharmAla’s Strategic Approach Post-Lykos CRL

PharmAla Biotech’s CEO Nick Kadysh On Psychedelics, the FDA, and PharmAla’s Strategic Approach Post-Lykos CRL